长期的ACE抑制可以使高血压大鼠的寿命翻倍
1Hoechst Marion Roussel, DG Research Cardiovascular, Frankfurt/Main, Germany. wolfgang.Linz@hmrag.com
Circulation
|December 31, 1997
概括
用ACE抑制剂拉米普利终身治疗使得容易中风的老鼠的寿命翻了一番,与健康对照相匹配. 这表明ACE抑制有潜力改善高血压和心血管疾病的生存率.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 高血压研究 高血压研究
背景情况:
- 容易中风的自发高血压大鼠 (SHR-SP) 和正常血压的Wistar-Kyoto (WKY) 大鼠被用于研究终身 ACE 抑制剂拉米普里尔治疗.
- 拉米普利尔在抗高血压和亚抗高血压剂量中被使用.
研究的目的:
- 为了比较终身拉米普利治疗对SHR-SP大鼠和WKY大鼠寿命和心血管参数的影响.
- 调查代理标记物,包括心脏缩,功能,新陈代谢和内皮功能.
主要方法:
- 135只SHR-SP和135只WKY大鼠被随机分为高剂量拉米普利 (HRA),低剂量拉米普利 (LRA) 或安慰剂组.
- 终身治疗是通过饮用水进行的,在15个月和30个月后进行评估,相当于安慰剂组中约80%的死亡率.
主要成果:
- 高剂量拉米普利尔 (HRA) 将SHR-SP大鼠的寿命翻了一番,达到30个月,与WKY对照匹配. 低剂量拉米普利 (LRA) 将寿命延长到18个月.
- 在SHR-SP大鼠中,HRA完全预防左心室缩. 这两种剂量都改善了心脏功能,新陈代谢和内皮功能.
- 拉米普利尔治疗增加了内皮NO合成酶的表达,并降低了心脏ACE表达/活性.
结论:
- 终身ACE抑制在SHR-SP大鼠中的寿命显著增加一倍,使其正常化为正常压力大鼠的寿命.
- 生存益处与保存的内皮功能,心脏健康和新陈代谢有关.
- 这些发现表明,ACE抑制可以改善高风险高血压和心血管疾病患者的生存率.
相关概念视频
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...